Zhejiang Huahai Pharmaceutical Co Ltd Total Liabilities
Zhejiang Huahai Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Zhejiang Huahai Pharmaceutical Co Ltd (600521) has total liabilities worth CN¥11.90 Billion CNY (≈ $1.74 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 600521 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Zhejiang Huahai Pharmaceutical Co Ltd (2000–2025)
Total liabilities of Zhejiang Huahai Pharmaceutical Co Ltd from 2000 to 2025. This chart illustrates how Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Zhejiang Huahai Pharmaceutical Co Ltd (600521) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Zhejiang Huahai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Huahai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Monday.Com Ltd
NASDAQ:MNDY
|
USA | $1.00 Billion |
|
Xiamen C&D Inc
SHG:600153
|
China | CN¥638.99 Billion |
|
Turk Telekomunikasyon AS
IS:TTKOM
|
Turkey | TL214.22 Billion |
|
Geovis Technology Co Ltd
SHG:688568
|
China | CN¥3.79 Billion |
|
Companhia de Saneamento de Minas Gerais
SA:CSMG3
|
Brazil | R$9.16 Billion |
|
Puig Brands SA
NYSE:PUGBY
|
USA | $4.64 Billion |
|
Doximity Inc
NYSE:DOCS
|
USA | $172.85 Million |
|
Edgewise Therapeutics Inc
NASDAQ:EWTX
|
USA | $25.32 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Zhejiang Huahai Pharmaceutical Co Ltd balance sheet assets.
Liquidity & Leverage Metrics
Zhejiang Huahai Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Zhejiang Huahai Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Huahai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Huahai Pharmaceutical Co Ltd (2000–2025)
The table below shows the annual total liabilities of Zhejiang Huahai Pharmaceutical Co Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥12.05 Billion ≈ $1.76 Billion |
+7.17% |
| 2024-12-31 | CN¥11.24 Billion ≈ $1.64 Billion |
+8.62% |
| 2023-12-31 | CN¥10.35 Billion ≈ $1.51 Billion |
-0.55% |
| 2022-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+19.72% |
| 2021-12-31 | CN¥8.69 Billion ≈ $1.27 Billion |
+38.70% |
| 2020-12-31 | CN¥6.27 Billion ≈ $917.01 Million |
+26.58% |
| 2019-12-31 | CN¥4.95 Billion ≈ $724.43 Million |
-19.64% |
| 2018-12-31 | CN¥6.16 Billion ≈ $901.51 Million |
+91.80% |
| 2017-12-31 | CN¥3.21 Billion ≈ $470.03 Million |
+49.50% |
| 2016-12-31 | CN¥2.15 Billion ≈ $314.40 Million |
+19.69% |
| 2015-12-31 | CN¥1.80 Billion ≈ $262.69 Million |
+44.31% |
| 2014-12-31 | CN¥1.24 Billion ≈ $182.03 Million |
-14.02% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+14.14% |
| 2012-12-31 | CN¥1.27 Billion ≈ $185.49 Million |
+21.01% |
| 2011-12-31 | CN¥1.05 Billion ≈ $153.28 Million |
+42.33% |
| 2010-12-31 | CN¥735.92 Million ≈ $107.69 Million |
+40.72% |
| 2009-12-31 | CN¥522.98 Million ≈ $76.53 Million |
+26.17% |
| 2008-12-31 | CN¥414.51 Million ≈ $60.66 Million |
+44.04% |
| 2007-12-31 | CN¥287.78 Million ≈ $42.11 Million |
+29.25% |
| 2006-12-31 | CN¥222.66 Million ≈ $32.58 Million |
+28.92% |
| 2005-12-31 | CN¥172.70 Million ≈ $25.27 Million |
+56.97% |
| 2004-12-31 | CN¥110.03 Million ≈ $16.10 Million |
+23.25% |
| 2003-12-31 | CN¥89.27 Million ≈ $13.06 Million |
-46.75% |
| 2002-12-31 | CN¥167.62 Million ≈ $24.53 Million |
+10.48% |
| 2001-12-31 | CN¥151.72 Million ≈ $22.20 Million |
+34.52% |
| 2000-12-31 | CN¥112.79 Million ≈ $16.50 Million |
-- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging componen… Read more